Adequan Canine launches $25,000 donation match campaign for service dog organization, Canine Companions Join Adequan® Canine (polysulfated glycosaminoglycan) and donate to Canine Companions® to help make more everyday adventures possible for service dog teams.
SHIRLEY, N.Y., Jan. 14, 2024 — For Don Jones, a firefighter and veteran diagnosed with PTSD, his service dog, Walla, is the glue that holds him together. Trained in over 40 tasks to help mitigate symptoms of PTSD, she helps him overcome nightmares, isolation and anxiety. With her calm, encouraging demeanor and skills, Walla helps Jones stay grounded.
“Life changing isn’t enough to express what Walla has done for me, Walla is my savior,” said Jones.
Jones matched with Walla through Canine Companions, a national non-profit organization that provides expertly trained service dogs to help provide self-sufficiency to people with disabilities, allowing them to enjoy their independence and quality of life. To help more people enjoy more everyday adventures with the assistance of a service dog, Adequan Canine is running a donation match initiative. The campaign will start Jan. 15 and last through March 15. Within that time frame, Adequan Canine will match every dollar donated to Canine Companions up to $25,000.
“I'm so thankful to Adequan Canine for matching donations at this time because without their support, there wouldn't be a me and Walla, and there wouldn't be future veteran service dog teams getting paired,” said Jones. “It’s not only that initial pairing and training. It’s all the supportive help afterwards that’s available to us through Canine Companions, which is only made possible through these generous donations.”
Since its founding, Canine Companions has paired more than 7,700 service dog teams. All were matched at no cost to clients, so those who contribute their time and/or money help make a big difference in the lives of those who receive a service dog through the organization.
“Adequan Canine is produced by a company dedicated to helping more dogs experience the everyday adventures life has to offer so we're excited to partner with an organization whose purpose is to do the same for humans,” said Joel Steckler, vice president and general manager, American Regent Animal Health.
If you would like to join Adequan Canine in helping to make more everyday adventures possible for service dog teams, donate today at canine.org.
About American Regent Animal Health American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 1-800-458-0163.
About Canine Companions Leading the service dog industry, Canine Companions transforms the lives of children, adults and veterans with disabilities by providing expertly trained service dogs that assist with practical tasks, as well as provide unconditional love and acceptance—all free of charge. This powerful relationship leads to increased independence, self-esteem and inclusion for a person with a disability. As the largest provider of service dogs for people with disabilities, Canine Companions has matched more than 7,700 life-changing service dogs trained in 45 tasks including retrieving dropped items, pulling a manual wheelchair, alerting to sounds in the environment and interrupting flashbacks and nightmares. Established in 1975, Canine Companions is a nonprofit 501(c)(3) with six training centers across the country serving all 50 states. Learn more about our program by visiting canine.org or calling 1-800-572-BARK. All trademarks are the property of their respective owners. © 2024, American Regent, Inc.
PP-AC-US-0601
Media Contact Susan Wright susan.wright@stephens-adv.com 816-678-4978
Survey highlights substantial need for canine osteoarthritis management protocol for veterinarians AAHA research reveals importance of resources, awareness focused on early-onset disease.
SHIRLEY, N.Y., Dec. 7, 2023 – A pivotal survey by the American Animal Hospital Association (AAHA), conducted in partnership with American Regent Animal Health and leading veterinary orthopedist Denis Marcellin-Little, DEDV, DACVS, DACVSMR, CCAT, has revealed a significant demand among participating veterinarians for a structured protocol to manage canine osteoarthritis, especially when it comes to early detection in younger dogs.
“We should be talking about osteoarthritis when it’s a non-issue—before it becomes a problem.” —Dr. Denis Marcellin-Little
An overwhelming 95% of veterinarians agree that a canine osteoarthritis protocol would be beneficial, signaling an urgent need for standardized care procedures. “It’s extremely rare that 95% of veterinarians would agree on anything,” said Dr. Marcellin-Little, a professor at the University of California, Davis, School of Veterinary Medicine. “This consensus is a cry for help—a clear demand for more structure in managing osteoarthritis.”
The survey, which garnered responses from nearly 800 veterinarians, also sheds light on practitioners’ self-assessment of their own knowledge. They gave themselves an average rating of 7/10 on understanding the onset of canine osteoarthritis—equivalent to a “C” grade, according to Dr. Marcellin-Little, who added, “We want them to all be ‘A’s.” When it comes to managing osteoarthritis, the average rating rises slightly to 8/10. “There’s a bit more confidence in management than in detection, which shows that we should be focusing on early onset,” Dr. Marcellin-Little added. With veterinarians estimating that 45% of their patients have osteoarthritis, 47% are predisposed to it, and 26% have early-onset disease, the survey highlights a critical window of opportunity for early intervention. “A quarter to half of our patients may be in the early stages of osteoarthritis,” explained Dr. Marcellin-Little. “This justifies a stronger emphasis on early detection.”
In addition, veterinarians say 75% of their clients know only “a little bit” about canine osteoarthritis, presenting an opportunity for better education and resources that boost understanding of what dog owners need to know about osteoarthritis. Still, despite the awareness gap, the survey revealed that less than 10% of veterinarians initiate discussions about osteoarthritis when they first begin a relationship with a dog and client. Dr. Marcellin-Little emphasized the importance of early conversations: “We should be talking about osteoarthritis when it’s a non-issue—before it becomes a problem.”
The findings are a call to action for the veterinary community to prioritize early osteoarthritis detection and management in clinical practice. This research from American Regent, maker of Adequan® Canine (polysulfated glycosaminoglycan), and AAHA is the first step in supporting veterinarians with the resources and protocols necessary to enhance dogs’ joint health and overall well-being.
Dr. Marcellin-Little will be presenting more insights on the survey findings during a lunch session on Sunday, Jan. 14, 2024, during the VMX veterinary conference in Orlando, Florida. Media are invited to attend the session and also speak with Dr. Marcellin-Little individually during the event. For additional details or to arrange interviews, email kristi.fender@stephens-adv.com. For more information on canine osteoarthritis and resources for veterinarians, visit adequancanine.com.
Adequan® Canine polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to polysulfated glycosaminoglycan (PSGAG) or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information at adequancanine.com.
PP-AC-US-0593
Adequan® Brands Announce Extended Shelf Life and Refreshed Packaging Updates help improve inventory management for veterinary teams.
Shirley, New York, April 05, 2022 – American Regent Animal Health, a division of American Regent, Inc., announces extended shelf life for Adequan® Canine (polysulfated glycosaminoglycan) and Adequan i.m. (polysulfated glycosaminoglycan). The FDA has approved increasing the expiration date for both products from 24 months to 36 months from date of manufacture.
In a separate submission, the FDA approved refreshed packaging for Adequan Canine, Adequan i.m. and BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension). The packaging updates include the following benefits:
“In addition to making the packaging more visually pleasing, the updates deliver improvements that reflect our support for busy veterinarians and technicians,” said Andy Ferrigno, Senior Director of Sales and Marketing for American Regent Animal Health. “They also highlight our ongoing commitment to these long-standing, proven products.”
Product with the extended expiration date and new packaging will begin arriving in the market this spring as existing supply is distributed and administered. For more information, contact an American Regent Animal Health sales representative or an authorized distributor representative.
PP-AI-US-0762 04/2022
Auburn University Faculty Clinician Selected for 2020 Grand Prize My Vet Rocks Award
Shirley, N.Y., December 7, 2020 – The American Association of Equine Practitioners (AAEP) salutes Dr. Alfredo Sanchez-Londoño, associate clinical professor, equine field service, at the Auburn University College of Veterinary Medicine in Auburn, Ala., as recipient of the grand prize 2020 My Vet Rocks Award.
Dr. Sanchez-Londoño is honored for his clinical proficiency, communication skills and deep-seated commitment to owner and student education. He was recognized Dec. 6 during the Opening Session of the AAEP’s 2020 Annual Convention & Trade Show, held virtually. Dr. Sanchez-Londoño received complimentary registration for the virtual convention and a grand prize package provided by the AAEP and contest sponsor American Regent Animal Health.
Throughout the summer, My Vet Rocks celebrated the important relationship between veterinarian, owner and horse. Horse owners were encouraged to nominate AAEP-member veterinarians who are exceptional in their care of the horse for monthly honors between June and August. Three veterinarians were selected for recognition each of those months in a Win-Place-Show order and highlighted on the AAEP website, monthly newsletter, bi-weekly e-newsletter and Facebook page.
According to Donna Tommelleo, one of Dr. Sanchez-Londoño’s nominators, “His approach to horses, horse owners and all things equine is rooted in constant learning, teaching and compassion. … He is ever the teacher and, just as important, ever the student, always in tune with the latest research and best practice. As a horse owner, you know Alfredo’s approach is at the forefront of what’s new, what’s next and what’s best.”
About AAEP The American Association of Equine Practitioners, headquartered in Lexington, Ky., was founded in 1954 as a non-profit organization dedicated to the health and welfare of the horse. Currently, AAEP reaches more than 5 million horse owners through its over 9,000 members worldwide and is actively involved in ethics issues, practice management, research and continuing education in the equine veterinary profession and horse industry.
PP-AI-US-0574 12/2020
Equine Veterinarians Enjoy Improved Access to Adequan® and DJD Resources American Regent Animal Health partnering with veterinary distributors to distribute Adequan®
Shirley, N.Y., December 2, 2020 – American Regent Animal Health announces it will begin selling Adequan® i.m. (polysulfated glycosaminoglycan) through veterinary distribution in December 2020. As of the date of this release, the company has finalized agreements with several national distributors. It is also working to expand this network to distribute the product and provide veterinarians with increased product support, streamlined ordering, and better access to resources that educate horse owners about the effects of equine degenerative joint disease (DJD).
“Listening to our customers and finding new opportunities to meet their needs is our top priority,” says Joel Steckler, Vice President and General Manager, Animal Health at American Regent. “In this spirit, we are pleased to make Adequan® i.m. available via veterinary distribution.”
Veterinarians will be able to purchase Adequan® i.m. from the distributor of their choice, while receiving continued support from dedicated American Regent Animal Health sales professionals and the company’s Technical Services Veterinarians. American Regent Animal Health has achieved success with a similar approach to distributing Adequan® Canine (polysulfated glycosaminoglycan), in which veterinarians report they appreciate the increased touchpoints and diversity of purchasing options.
To better support this distribution channel, American Regent Animal Health will redesign its equine sales team model in the coming weeks. Coupled with the company’s distribution partners, the revamped structure will enable American Regent Animal Health to increase its already strong industry involvement.
“Engaging with the equine community is one of the central tenets of what we do,” Steckler says. “Combined with our ongoing investment in and commitment to research and development, our team looks forward to continued connections and reaching more veterinarians across the country so they’re able to support more horses with DJD.”
INDICATIONS Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, visit www.adequan.com.
About American Regent Animal Health American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
New Podcast Gives a Peek Behind the Barn Door of Legendary Equestrians During this time apart, “Stories in Stride” brings the horse community together through first-person accounts of success, disappointment, perseverance and hope.
Melville, New York, July 15, 2020 – American Regent Animal Health, maker of Adequan® i.m. (polysulfated glycosaminoglycan), announces the launch of "Stories in Stride," a podcast that provides a glimpse into the lives and journeys of exceptional equestrians and equine professionals. Hosted by Allyn Mann, Director of Strategic Partnerships for American Regent Animal Health, the podcast transcends disciplines to inspire and uplift everyone who shares a love of the horse.
"The equine community is rich with amazing individuals whose stories are humbling, humorous and invigorating," Mann says. "It’s a privilege to bring them to light as a way of honoring history, addressing current challenges and highlighting an optimistic future we can shape together through our joint devotion to horses and equine sport."
Each "Stories in Stride" episode features a one-on-one conversation with an elite rider, trainer or veterinarian, including:
The initial installments of "Stories in Stride" are available now, and new episodes will be released throughout the year. "Stories in Stride" can be accessed from Apple Podcasts, Google Podcasts and Spotify or your favorite podcast platform.
About American Regent Animal Health American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
PP-AI-US-0506 7/2020
Adequan® i.m. (polysulfated glycosaminoglycan) to Relaunch in Europe Following New Distributor Partnership Agreement
Shirley, N.Y., January 6, 2020 – American Regent Animal Health, a division of American Regent, Inc., manufacturer of Adequan® i.m. (polysulfated glycosaminoglycan) for horses announces a new partnership with Animalcare Group plc to relaunch Adequan i.m. in Europe.
Through the exclusive distribution agreement with American Regent Animal Health, Animalcare Group plc will work toward relaunching Adequan i.m. in Europe and selected markets following necessary regulatory approvals. Adequan i.m. has been unavailable for several years in Europe due to a supply issue that has now been fully resolved.
“We are excited to be working with American Regent Animal Health to bring this important product back to the market and look forward to relaunching it following necessary European regulatory review,” says Jenny Winter, CEO of Animalcare Group plc.
“The Animalcare partnership is an important first step in returning Adequan i.m. to veterinarians outside of North America,” says Andy Ferrigno, Head of Commercial Development for American Regent Animal Health. “We are working diligently with the team at Animalcare and regulatory officials toward a smooth relaunch in Europe, but we still have some work to do. A more definitive timeline for relaunch in Europe will be provided in the coming months.”
Adequan i.m. has been marketed in the United States for 30 years for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
About American Regent Animal Health American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.
About Animalcare Group plc Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition. For more information, visit www.animalcaregroup.co.uk.
PP-AI-US-0326 12/2019
Be the first to hear about important news and product information! First, select the one that best describes you. Then we’ll take you to our sign up page.